Trillium Therapeutics (NASDAQ: TRIL) and XOMA Corporation (NASDAQ:XOMA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

Trillium Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, XOMA Corporation has a beta of 3.05, meaning that its share price is 205% more volatile than the S&P 500.

Institutional & Insider Ownership

48.0% of Trillium Therapeutics shares are owned by institutional investors. Comparatively, 32.9% of XOMA Corporation shares are owned by institutional investors. 3.0% of XOMA Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Trillium Therapeutics and XOMA Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trillium Therapeutics N/A -178.08% -61.40%
XOMA Corporation -329.42% N/A -155.46%

Valuation and Earnings

This table compares Trillium Therapeutics and XOMA Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trillium Therapeutics N/A N/A -$27.43 million ($3.73) -1.27
XOMA Corporation $12.31 million 11.29 -$30.55 million ($7.32) -2.50

Trillium Therapeutics has higher revenue, but lower earnings than XOMA Corporation. XOMA Corporation is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Trillium Therapeutics and XOMA Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trillium Therapeutics 0 0 6 0 3.00
XOMA Corporation 0 2 2 0 2.50

Trillium Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 247.37%. XOMA Corporation has a consensus price target of $17.00, indicating a potential downside of 7.05%. Given Trillium Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Trillium Therapeutics is more favorable than XOMA Corporation.

Summary

Trillium Therapeutics beats XOMA Corporation on 8 of the 12 factors compared between the two stocks.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.